| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
MBX Biosciences, Inc.
13D/A
MBX · 55287L101
|
4.8% |
9/30/2025
Event 9/26/2025
|
||||
| Norwest Venture Partners XVI, LP | 4.8% | |||||
| Genesis VC Partners XVI, LLC | 4.8% | |||||
| NVP Associates, LLC | 4.8% | |||||
| Jeffrey Crowe | 4.8% | |||||
| Jon Erik Kossow | 4.8% | |||||
| Tiba Aynechi | 4.8% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.